Induced cancer stem-like cells as a model for biological screening and discovery of agents targeting phenotypic traits of cancer stem cell

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8665-8680

  Nishi, Mayuko ^a   Akutsu, Hidenori ^b   Kudoh, Ayumi ^a   Kimura, Hirokazu ^c   Yamamoto, Naoki ^d   Umezawa, Akihiro ^b   Lee, Sam W ^e   Ryo, Akihide ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Cancer stem cell; Drug screening; P21Cip1; Senescence; Tumor sphere formation

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; WITHAFERIN A; ANTINEOPLASTIC AGENT; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A; WITHANOLIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER STEM CELL; CARCINOGENESIS; CARCINOGENICITY; CELL RENEWAL; CELL VIABILITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; IN VITRO STUDY; IN VIVO STUDY; MORPHOLOGICAL TRAIT; MOUSE; NONHUMAN; PLURIPOTENT STEM CELL; PROTEIN EXPRESSION; ANIMAL; BAGG ALBINO MOUSE; CELL AGING; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; GENETIC TRANSFECTION; GENETICS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTICELLULAR SPHEROID; NUCLEAR REPROGRAMMING; NUDE MOUSE; PATHOLOGY; PHENOTYPE; PROCEDURES; SIGNAL TRANSDUCTION; TIME;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL AGING; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; CELLULAR REPROGRAMMING; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; EPITHELIAL-MESENCHYMAL TRANSITION; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION; SPHEROIDS, CELLULAR; TIME FACTORS; TRANSFECTION; WITHANOLIDES;

EID: 84907999055     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2356     Document Type: Article

References (57)

1. Clevers H. The cancer stem cell: premises, promises and challenges. Nat Med. 2011; 17(3):313-319.
2. Visvader JE and Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8(10):755-768.
3. Alison MR, Lim SM and Nicholson LJ. Cancer stem cells: problems for therapy? J Pathol. 2011; 223(2):147-161.
4. Hanahan D and Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-674.
5. Dean M, Fojo T and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005; 5(4):275-284.
6. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-760.
7. Liu S and Wicha MS. Targeting breast cancer stem cells. J Clin Oncol. 2010; 28(25):4006-4012.
8. Sundberg SA. High-throughput and ultra-high-throughput screening: solution-and cell-based approaches. Curr Opin Biotechnol. 2000; 11(1):47-53.
9. Wilding JL and Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014; 74(9):2377-2384.
10. Singh AK, Arya RK, Maheshwari S, Singh A, Meena S, Pandey P, Dormond O and Datta D. Tumor heterogeneity and cancer stem cell paradigm: Updates in concept, controversies and clinical relevance. Int J Cancer. 2014.
11. Scaffidi P and Misteli T. In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol. 2011; 13(9):1051-1061.
12. Kao CY, Oakley CS, Welsch CW and Chang CC. Growth requirements and neoplastic transformation of two types of normal human breast epithelial cells derived from reduction mammoplasty. In Vitro Cell Dev Biol Anim. 1997; 33(4):282-288.
13. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100(7):3983-3988.
14. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J and Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63(18):5821-5828.
15. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, Brown M, Viens P, Xerri L, Bertucci F, Stassi G, Dontu G, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69(4):1302-1313.
16. Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA and Allan AL. High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 2009; 13(8B):2236-2252.
17. Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, Pilotti S, Pierotti MA and Daidone MG. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005; 65(13):5506-5511.
18. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J and Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008; 133(4):704-715.
19. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 2009; 138(4):645-659.
20. Calvet CY, Andre FM and Mir LM. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PLoS One. 2014; 9(2):e89644.
21. Soule HD, Maloney TM, Wolman SR, Peterson WD, Jr., Brenz R, McGrath CM, Russo J, Pauley RJ, Jones RF and Brooks SC. Isolation and characterization of a spontaneously immortalized human breast epithelial cell line, MCF-10. Cancer Res. 1990; 50(18):6075-6086.
22. Nishi M, Sakai Y, Akutsu H, Nagashima Y, Quinn G, Masui S, Kimura H, Perrem K, Umezawa A, Yamamoto N, Lee SW and Ryo A. Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors. Oncogene. 2014; 33(5):643-652.
23. Cruz FD and Matushansky I. Solid tumor differentiation therapy-is it possible? Oncotarget. 2012; 3(5):559-567.
24. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K and Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131(5):861-872.
25. Blagosklonny MV. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther. 2007; 6(11):1684-1690.
26. Singh N, Bhalla M, de Jager P and Gilca M. An overview on ashwagandha: a Rasayana (rejuvenator) of Ayurveda. Afr J Tradit Complement Altern Med. 2011; 8(5 Suppl):208-213.
27. Sedelnikova OA, Horikawa I, Zimonjic DB, Popescu NC, Bonner WM and Barrett JC. Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks. Nat Cell Biol. 2004; 6(2):168-170.
28. Leontieva OV, Lenzo F, Demidenko ZN and Blagosklonny MV. Hyper-mitogenic drive coexists with mitotic incompetence in senescent cells. Cell Cycle. 2012; 11(24):4642-4649.
29. Cowell JK, LaDuca J, Rossi MR, Burkhardt T, Nowak NJ and Matsui S. Molecular characterization of the t(3;9) associated with immortalization in the MCF10A cell line. Cancer Genet Cytogenet. 2005; 163(1):23-29.
30. Leontieva OV, Demidenko ZN and Blagosklonny MV. MEK drives cyclin D1 hyperelevation during geroconversion. Cell Death Differ. 2013; 20(9):1241-1249.
31. Leontieva OV, Demidenko ZN and Blagosklonny MV. S6K in geroconversion. Cell Cycle. 2013; 12(20):3249-3252.
32. Abbas T and Dutta A. p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer. 2009; 9(6):400-414.
33. Kondo T. Stem cell-like cancer cells in cancer cell lines. Cancer Biomark. 2007; 3(4-5):245-250.
34. Medema JP. Cancer stem cells: the challenges ahead. Nat Cell Biol. 2013; 15(4):338-344.
35. Kaul MK, Kumar A, Ahuja A, Mir BA, Suri KA and Qazi GN. Production dynamics of Withaferin A in Withania somnifera (L.) Dunal complex. Nat Prod Res. 2009; 23(14):1304-1311.
36. Vyas AR and Singh SV. Molecular targets and mechanisms of cancer prevention and treatment by withaferin a, a naturally occurring steroidal lactone. AAPS J. 2014; 16(1):1-10.
37. Hahm ER, Lee J, Kim SH, Sehrawat A, Arlotti JA, Shiva SS, Bhargava R and Singh SV. Metabolic alterations in mammary cancer prevention by withaferin A in a clinically relevant mouse model. J Natl Cancer Inst. 2013; 105(15):1111-1122.
38. Oh JH, Lee TJ, Kim SH, Choi YH, Lee SH, Lee JM, Kim YH, Park JW and Kwon TK. Induction of apoptosis by withaferin A in human leukemia U937 cells through down-regulation of Akt phosphorylation. Apoptosis. 2008; 13(12):1494-1504.
39. Lee J, Sehrawat A and Singh SV. Withaferin A causes activation of Notch2 and Notch4 in human breast cancer cells. Breast Cancer Res Treat. 2012; 136(1):45-56.
40. Roy RV, Suman S, Das TP, Luevano JE and Damodaran C. Withaferin A, a steroidal lactone from Withania somnifera, induces mitotic catastrophe and growth arrest in prostate cancer cells. J Nat Prod. 2013; 76(10):1909-1915.
41. Kim SH and Singh SV. Mammary Cancer Chemoprevention by Withaferin A Is Accompanied by In Vivo Suppression of Self-Renewal of Cancer Stem Cells. Cancer Prev Res (Phila). 2014.
42. Arden KC. FoxO: linking new signaling pathways. Mol Cell. 2004; 14(4):416-418.
43. Cheng T, Rodrigues N, Shen H, Yang Y, Dombkowski D, Sykes M and Scadden DT. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science. 2000; 287(5459):1804-1808.
44. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, Johnson M, Fortina P, Hyslop T, Windle JJ and Pestell RG. p21CIP1 attenuates Ras-and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci U S A. 2009; 106(45):19035-19039.
45. Roninson IB. Tumor cell senescence in cancer treatment. Cancer Res. 2003; 63(11):2705-2715.
46. Serrano M. Cancer: a lower bar for senescence. Nature. 2010; 464(7287):363-364.
47. Rodier F and Campisi J. Four faces of cellular senescence. J Cell Biol. 2011; 192(4):547-556.
48. Vazquez-Martin A, Lopez-Bonetc E, Cufi S, Oliveras-Ferraros C, Del Barco S, Martin-Castillo B and Menendez JA. Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions. Drug Resist Updat. 2011; 14(4-5):212-223.
49. Del Barco S, Vazquez-Martin A, Cufi S, Oliveras-Ferraros C, Bosch-Barrera J, Joven J, Martin-Castillo B and Menendez JA. Metformin: multi-faceted protection against cancer. Oncotarget. 2011; 2(12):896-917.
50. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, Come C, Savagner P, Gitelman I, Richardson A and Weinberg RA. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-939.
51. Smit MA and Peeper DS. Epithelial-mesenchymal transition and senescence: two cancer-related processes are crossing paths. Aging (Albany NY). 2010; 2(10):735-741.
52. Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C and Puisieux A. Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence. Cancer Cell. 2008; 14(1):79-89.
53. Lee KE and Bar-Sagi D. Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. Cancer Cell. 2010; 18(5):448-458.
54. Polyak K and Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009; 9(4):265-273.
55. Trost TM, Lausch EU, Fees SA, Schmitt S, Enklaar T, Reutzel D, Brixel LR, Schmidtke P, Maringer M, Schiffer IB, Heimerdinger CK, Hengstler JG, Fritz G, Bockamp EO, Prawitt D, Zabel BU, et al. Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells. Cancer Res. 2005; 65(3):840-849.
56. Ryo A, Uemura H, Ishiguro H, Saitoh T, Yamaguchi A, Perrem K, Kubota Y, Lu KP and Aoki I. Stable suppression of tumorigenicity by Pin1-targeted RNA interference in prostate cancer. Clin Cancer Res. 2005; 11(20):7523-7531.
57. Nishi M, Akutsu H, Masui S, Kondo A, Nagashima Y, Kimura H, Perrem K, Shigeri Y, Toyoda M, Okayama A, Hirano H, Umezawa A, Yamamoto N, Lee SW and Ryo A. A distinct role for Pin1 in the induction and maintenance of pluripotency. J Biol Chem. 2011; 286(13):11593-11603.